Abstract: A method performed by a client device is provided. The method includes obtaining, by a client device, data for transmission to a network server. The method includes determining, by the client device, a plurality of intermediate network nodes for transmission of the data, wherein the plurality of the intermediate network nodes are communicatively coupled to the network server. The method includes encoding, by the client device, the data using an encoding scheme. The method includes transmitting, by the client device and according to a data transmission scheme, a plurality of instances of the encoded data to the plurality of intermediate network nodes for aggregation by the intermediate network nodes with data received from one or more other client devices. Also provided are methods performed by an intermediate network node and a network server. The methods can be performed by one or more processors of an apparatus.

Abstract: Nanofiber filter media ribbons are flexible elongate strips of polymeric material having a surface on which is formed an array of nanofibers. Ribbons are formable into woven or non-woven mats. The array of nanofibers can be configured to filter a predetermined contaminant from a fluid stream passing through the mats. Filter ribbons are formable by applying a moldable polymer to a first angular location of a rotating cylindrical roll having an array of nanoholes formed in a circumferential surface thereof so that the polymer covers the surface of the roll and infiltrates the nanoholes; cooling the polymer while rotating the polymer-covered roll to a second angular position; and removing the cooled polymer from the roll as an elongate film having an array of nanofibers formed on a surface thereof by the polymer that infiltrated the nanoholes.

Abstract: Provided herein are T-cell receptor (TCR) fusion proteins (TFPs). T-cells engineered to express one or more TFPs. and methods of use thereof for the treatment of diseases, including cancer.

Abstract: Provided herein are T cell receptor (TCR) fusion proteins (TFPs) comprising CD70 binding domains, T cells engineered to express one or more TFPs, antibodies that specifically bind CD70, and methods of use thereof for the treatment of diseases, including cancer.

Abstract: Provided herein are T-cell receptor (TCR) fusion proteins (TFPs), T-cells engineered to express one or more TFPs, and methods of use thereof for the treatment of diseases, including cancer.

Abstract: Provided herein are recombinant nucleic acids encoding a T cell receptor (TCR) fusion protein (TFP) and an interleukin-15 (IL-15) polypeptide and/or an interleukin-15 receptor alpha (IL-15R?) polypeptide, modified T cells expressing the encoded molecules, and methods of use thereof for the treatment of diseases, including cancer.

Abstract: Provided herein are T-cell receptor (TCR) fusion proteins (TFPs) having specificity for one or more tumor cell associated antigens, T cells engineered to express one or more TFP, and methods of use thereof for the treatment of diseases, including cancer.

Abstract: Provided herein are recombinant nucleic acids encoding T cell receptor (TCR) fusion proteins (TFPs), modified human immune cells expressing the encoded molecules, and methods of use thereof for the treatment of diseases, including autoinmmune diseases.

Abstract: Provided herein are T-cell receptor (TCR) fusion proteins (TFPs), T-cells engineered to express one or more TFPs, and methods of use thereof for the treatment of diseases, including cancer.

Abstract: Disclosed herein are methods for treatment of a mesothelin (MSLN)-expressing cancer in a human subject comprising administration of, e.g., a plurality of anti-MSLN T cell receptor fusion protein (TFP)-expressing T cells. A ratio of CD4+ to CD8+ T cells in a sample from the human subject may have been determined before the administration of the plurality of anti-MSLN TFP-expressing T cells. The plurality of anti-MSLN TFP-expressing T cells may comprise a pre-determined ratio of CD4+ to CD8+ T cells.

Abstract: Provided herein are recombinant nucleic acids encoding T cell receptor (TCR) fusion proteins (TFPs), modified ?? T cells expressing the encoded molecules, and methods of use thereof for the treatment of diseases, including cancer.

Abstract: Provided herein are recombinant nucleic acids encoding T cell receptor (TCR) fusion proteins (TFPs), modified human immune cells expressing the encoded molecules, and methods of use thereof for the treatment of diseases, including cancer.

Abstract: Provided herein are T-cell receptor (TCR) fusion proteins (TFPs), T-cells engineered to express one or more TFPs, and methods of use thereof for the treatment of diseases, including cancer.

Abstract: Provided herein are T-cell receptor (TCR) fusion proteins (TFPs), T-cells engineered to express one or more TFPs, and methods of use thereof for the treatment of diseases, including cancer.

Abstract: Provided herein are T-cell receptor (TCR) fusion proteins (TFPs), T-cells engineered to express one or more TFPs, and methods of use thereof for the treatment of diseases, including cancer.

Abstract: Provided herein are recombinant nucleic acids encoding T cell receptor (TCR) fusion proteins (TFPs) and a TCR constant domain, modified T cells expressing the encoded molecules, and methods of use thereof for the treatment of diseases, including cancer.

Abstract: Provided herein are T cell receptor (TCR) fusion proteins (TFPs), T cells engineered to express one or more MUC16 or IL 13R?2 or MSLN TFPs, and methods of use thereof for the treatment of diseases, including cancer.

Abstract: Provided herein are T cell receptor (TCR) fusion proteins (TFPs) having specificity for more than one tumor cell associated antigen, T cells engineered to express one or more TFP, and methods of use thereof for the treatment of diseases, including cancer.

Abstract: Provided herein are T-cell receptor (TCR) fusion proteins (TFPs), T-cells engineered to express one or more TFPs, and methods of use thereof for the treatment of diseases, including cancer.

Abstract: Provided herein are T-cell receptor (TCR) fusion proteins (TFPs), T-cells engineered to express one or more TFPs, and methods of use thereof for the treatment of diseases, including cancer.